ERBB2 and breast cancer: In comparison to chemotherapy, the probabilities of T-DXd being considered cost-effective were 81.10%, 82.27%, and 73.78%, respectively, based on a WTP threshold of $100,000/QALY for patients with HER2-low advanced BC patients, HER2+ advanced BC patients, and HER2- advanced BC patients.